Are Jardiance and Ozempic in the same class?

No. Jardiance is an SGLT2 inhibitor acting in the kidney; Ozempic is a GLP-1 receptor agonist acting through gut hormone receptors. Different classes, different mechanisms, different routes.

Which one has the boxed warning?

Ozempic, with the thyroid C-cell tumor warning of the GLP-1 class. The Jardiance label carries no boxed warning.

Is Jardiance approved for weight loss like Ozempic is said to be?

Neither is. Weight reduction appears in neither label as an approved use: the Ozempic label covers type 2 diabetes and its complications, and semaglutide's weight approval belongs to a different product, Wegovy. The Jardiance label covers diabetes, heart failure and kidney disease.

Type 2 diabetesTwo labels compared

Jardiance vs Ozempic

Jardiance and Ozempic are both mainstays of type 2 diabetes treatment and work in entirely different places: Jardiance in the kidney, sending glucose out with urine; Ozempic through GLP-1 receptors, acting on insulin, glucagon and appetite. One is a daily tablet without a boxed warning, the other a weekly injection with the boxed warning of its class. This page compares the two labels.

Jardiance

Ingredient: Empagliflozin
Approved for: Type 2 diabetes, heart failure, chronic kidney diseasecovers type 2 diabetes
Supply: Prescription
Boxed warning: None
Pharmacy cost: $11.20 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter

Boehringer Ingelheim Pharmaceuticals, Inc.. Label version 31, effective 30 January 2026.

Ozempic injection

Ingredient: Semaglutide
Approved for: Type 2 diabetes, with cardiovascular and kidney indicationscovers type 2 diabetes
Supply: Prescription
Boxed warning: WARNING: RISK OF THYROID C-CELL TUMORS
Pharmacy cost: $331.97 per milliliter, brandwhat pharmacies pay to buy it, not the price at the counter

A-S Medication Solutions. Label version 1, effective 30 July 2026.

01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Label section	JardianceEmpagliflozin	Ozempic injectionSemaglutide
Active ingredient	JardianceEmpagliflozinSGLT2 inhibitor	Ozempic injectionSemaglutideGLP-1 receptor agonist
Approved for	JardianceType 2 diabetes, heart failure, chronic kidney disease	Ozempic injectionType 2 diabetes, with cardiovascular and kidney indications
Supplysame in both	JardiancePrescription	Ozempic injectionPrescription
What pharmacies payAcquisition cost, not retail	Jardiance$11.20 per tablet, capsule or pen, brand	Ozempic injection$331.97 per milliliter, brand
Boxed warning	JardianceNone	Ozempic injectionWARNING: RISK OF THYROID C-CELL TUMORS
What the FDA approved it for	Jardiance JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. JARDIANCE is not expected to be effective in these populations.	Ozempic injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Forms and strengths	Jardiance JARDIANCE tablets available as: 10 mg pale yellow, round, biconvex and bevel-edged, film-coated tablets debossed with "S 10" on one side and the Boehringer Ingelheim company symbol on the other side. 25 mg pale yellow, oval, biconvex, film-coated tablets debossed with "S 25" on one side and the Boehringer Ingelheim company symbol on the other side. Tablets: 10 mg, 25 mg	Ozempic injection Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens Injection: 0.25 mg, 0.5 mg or 1 mg per 0.5 mL in a single-dose prefilled syringe
How the label says it is taken	Jardiance Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating. Recommended dosage is 10 mg orally once daily in the morning, taken with or without food. For additional glycemic control, dosage may be increased to 25 mg orally once daily in patients tolerating JARDIANCE. Withhold JARDIANCE for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting.	Ozempic injection Administer once weekly at any time of day, with or without meals. Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage. If a dose is missed, administer within 5 days of missed dose. Inject subcutaneously in the abdomen, thigh, or upper arm. Important Administration Instructions
Most common adverse reactions	Jardiance Most common adverse reactions (5% or greater incidence) were urinary tract infections and female genital mycotic infections To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc.	Ozempic injection most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation.
Warnings and precautions	Jardiance Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis: Consider ketone monitoring in patients with type 1 diabetes mellitus and consider ketone monitoring in others at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue JARDIANCE if ketoacidosis is suspected. Volume Depletion: Before initiating JARDIANCE, assess volume status and renal function in patients with impaired renal function, elderly patients, or patients on loop diuretics. Monitor for signs and symptoms during therapy. Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier's Gangrene), and Genital Mycotic Infections: Monitor patients for signs and symptoms of genitourinary infections and treat promptly, if indicated. Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher regardless of insulin use. Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE. Lower Limb Amputation: Monitor patients for infections or ulcers of lower limbs, and institute appropriate treatment Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., angioedema) have occurred with JARDIANCE. If hypersensitivity reactions occur, discontinue JARDIANCE, treat promptly, and monitor until signs and symptoms resolve.	Ozempic injection Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including OZEMPIC. Discontinue if pancreatitis is suspected. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored. Never share an OZEMPIC pen between patients, even if the needle is changed. Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. OZEMPIC is not recommended in patients with severe gastroparesis. Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue OZEMPIC if suspected and promptly seek medical advice. Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated.
Contraindications	Jardiance JARDIANCE is contraindicated in patients: with a hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such as angioedema have occurred. Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE.	Ozempic injection Personal or family history of MTC or in patients with MEN 2. Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC.
Drug interactions	Jardiance See Table 4 for clinically relevant interactions with JARDIANCE. See full prescribing information for information on drug interactions and interference of JARDIANCE with laboratory tests.	Ozempic injection Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.
Label version	Jardiance30 January 2026	Ozempic injection30 July 2026

03Written by us

The indications overlap in the middle, not at the edges

Both labels cover glycemic control in type 2 diabetes and a cardiovascular indication in adults with type 2 diabetes and established cardiovascular disease. From there they diverge: Jardiance covers heart failure and chronic kidney disease with or without diabetes, and its glycemic indication reaches children aged 10 and older. Ozempic's kidney indication is written for adults with type 2 diabetes and chronic kidney disease together, and all three of its indications are adult-only.

04Written by us

A tablet without a box against an injection with one

Jardiance is taken once daily in the morning, with or without food, and its label carries no boxed warning. Ozempic is injected once weekly, and its label opens with the boxed warning on thyroid C-cell tumors shared by the GLP-1 class, with the contraindication for medullary thyroid carcinoma history and MEN 2.

05Written by us

What this page does not tell you

It does not say which medication fits a particular person, and it does not address taking them together: combination treatment is a prescribing decision built by a clinician, and neither label ranks itself against the other.

06Written by us

Common questions

Are Jardiance and Ozempic in the same class?: No. Jardiance is an SGLT2 inhibitor acting in the kidney; Ozempic is a GLP-1 receptor agonist acting through gut hormone receptors. Different classes, different mechanisms, different routes.
Which one has the boxed warning?: Ozempic, with the thyroid C-cell tumor warning of the GLP-1 class. The Jardiance label carries no boxed warning.
Is Jardiance approved for weight loss like Ozempic is said to be?: Neither is. Weight reduction appears in neither label as an approved use: the Ozempic label covers type 2 diabetes and its complications, and semaglutide's weight approval belongs to a different product, Wegovy. The Jardiance label covers diabetes, heart failure and kidney disease.

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

FDA prescribing information for Jardiance
Boehringer Ingelheim Pharmaceuticals, Inc.. Label version 31, effective 30 January 2026.
Full label on DailyMed Approval record NDA204629
FDA prescribing information for Ozempic injection
A-S Medication Solutions. Label version 1, effective 30 July 2026.
Full label on DailyMed Approval record NDA209637

Each stripe is one section of the label, each division in a stripe one entry in that section. The red bar marks a boxed warning.

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.